Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...

A large new study has shed light on the wider health impacts of taking Ozempic-style drugs. Weight-loss drugs like Ozempic ...

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

GLP-1 drugs like Ozempic have swept the world as effective therapies for far more than their original target of diabetes.

An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...